fda warning letters compounded semaglutide 2024 2025 Letter to FDA's Office of Prescription Drug Promotion, CDER – Partnership for Safe Medicines The FDA has received reports

Clinicians avoid prescribing GLP-1 agonists for individuals with a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2A (MEN 2A), or type 2B (MEN 2B) (51)(53)

Knowing your options and advocating for your health will make this stage of life much more manageable.

Experimental evidence indicates that weight loss achieved through GLP-1 RAs is evaluated more negatively than lifestyle-based weight loss, reinforcing moralized distinctions regarding effort and legitimacy [86]

However, this standard NPO protocol assumes normal stomach emptying

Secondary bile acids are generated in the intestine through microbial biotransformations including deconjugation, dihydroxylation, dehydrogenation, oxidationreduction, desulfation, esterification, epimerization, and amidation of primary bile acids, and are not produced de novo within the CNS [61]